SAN DIEGO, Sept. 3, 2013 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the
Company's Chief Financial Officer, Brandi
L. Roberts, will present at the Rodman & Renshaw 15th
Annual Healthcare Conference, on Tuesday,
September 10th, 2013 at 10:50 a.m. Eastern time in Room 7.03 at The
Millenium Broadway Hotel in New York
City.
Interested parties can access a live audio webcast and slide
presentation on the Mast Therapeutics web site at
www.masttherapeutics.com. An archived presentation will be
available on the web site for 30 days.
About Mast Therapeutics
Mast Therapeutics, Inc. is a
publicly traded biopharmaceutical company headquartered in
San Diego, California. The
Company is leveraging the MAST (Molecular Adhesion and Sealant
Technology) platform, derived from over two decades of clinical,
nonclinical and manufacturing experience with purified and
non-purified poloxamers, to develop MST-188, its lead product
candidate, for serious or life-threatening diseases with
significant unmet needs. MST-188 is a cytoprotective,
hemorheologic, anti-inflammatory and anti-thrombotic agent that has
potential utility in diseases or conditions characterized by
microcirculatory insufficiency (endothelial dysfunction and/or
impaired blood flow).
The Company is enrolling subjects in EPIC, a pivotal phase 3
study of MST-188 in sickle cell disease. The Company plans to
initiate a phase 2 clinical study of MST-188 in acute limb
ischemia, a complication of peripheral arterial disease, in early
2014. More information can be found on the Company's web site
at www.masttherapeutics.com.
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Forward Looking Statements
Mast Therapeutics cautions
you that statements included in this press release that are not a
description of historical facts are forward-looking statements that
are based on the Company's current expectations and assumptions.
Such forward-looking statements include, but are not limited to,
statements regarding the Company's development plans for MST-188 in
acute limb ischemia, including the timing of initiation of the
planned phase 2 study. Among the factors that could cause or
contribute to material differences between the Company's actual
results and the expectations indicated by the forward-looking
statements are risks and uncertainties that include, but are not
limited to: delays in the commencement of clinical studies,
including as a result of difficulties in obtaining regulatory
agency agreement on clinical development plans or clinical study
design, opening trial sites, enrolling study subjects and
manufacturing sufficient quantities of clinical trial material; the
potential for institutional review boards or the FDA or other
regulatory agencies to require additional nonclinical or clinical
studies prior to initiation of a planned clinical study; and other
risks and uncertainties more fully described in the Company's press
releases and periodic filings with the Securities and Exchange
Commission. The Company's public filings with the Securities and
Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. Mast
Therapeutics does not intend to revise or update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date hereof,
except as may be required by law.
(Logo:
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)
SOURCE Mast Therapeutics